Benzinga | Aug 31, 2021 08:06AM EDT

Phio Pharmaceuticals Announces Upcoming Data Presentation At ESMO Virtual Congress 2021

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL(tm)) therapeutic platform, today announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

Details are as follows:

Event: ESMO Virtual Congress 2021

Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAiTitle: elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors

Authors: Benjamin Cuiffo, et al.

Abstract #4154Number:

Date: September 16-21, 2021

An archived version of the Phio presentation will be made available on the "Investors -- Events and Presentations" section of the Company's website (click here).